Sino Medical Sciences Technology Inc. (SHA:688108)
China · Delayed Price · Currency is CNY 15.47
+0.15 (0.98%)
Sep 14, 2026, 11:29 AM CST
SHA:688108 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 589.41 | 525.25 | 457.94 | 340.02 | 192.58 | 194.1 |
Other Revenue | 0.16 | 0.16 | 0.8 | 3.23 | 0.27 | 0.26 |
| 589.57 | 525.41 | 458.74 | 343.26 | 192.85 | 194.36 | |
Revenue Growth | 21.43% | 14.53% | 33.64% | 77.99% | -0.77% | -40.64% |
Cost of Revenue | 184.28 | 180.9 | 192.64 | 145.64 | 85.64 | 60.25 |
Gross Profit | 405.29 | 344.51 | 266.1 | 197.62 | 107.21 | 134.11 |
Selling, General & Admin | 170.29 | 168.19 | 168.45 | 157.77 | 174.76 | 150.02 |
Research & Development | 116.58 | 122.57 | 140.56 | 114.1 | 152.8 | 148.93 |
Other Operating Expenses | 7.5 | -1.65 | -7.5 | 2.15 | 0.77 | 1.8 |
Operating Expenses | 294.63 | 289.38 | 301.08 | 272.61 | 329.66 | 300.21 |
Operating Income | 110.65 | 55.13 | -34.98 | -74.99 | -222.45 | -166.1 |
Interest Expense | -5.05 | -5.05 | -5.61 | -3.75 | -2.55 | -2.2 |
Interest & Investment Income | 2.23 | 2.15 | 13.62 | 2.63 | 2.98 | 4.68 |
Currency Exchange Gain (Loss) | -1.07 | -1.07 | -0.19 | -1.01 | 0.52 | -0.57 |
Other Non Operating Income (Expenses) | -2.31 | -0.22 | -0.22 | -0.18 | -0.17 | -0.16 |
EBT Excluding Unusual Items | 104.46 | 50.95 | -27.39 | -77.3 | -221.67 | -164.36 |
Gain (Loss) on Sale of Investments | - | - | - | -4.67 | -4.11 | -0.29 |
Gain (Loss) on Sale of Assets | -0.08 | -0.07 | 0.2 | -1.55 | -2.21 | 0.11 |
Asset Writedown | -9.36 | - | - | - | - | - |
Other Unusual Items | 17.57 | 17.57 | 10.03 | 15.66 | 6.65 | 1.43 |
Pretax Income | 112.59 | 68.45 | -17.16 | -67.86 | -221.34 | -163.1 |
Income Tax Expense | 22.72 | 20.98 | -13.27 | -24.46 | -48.03 | -31.8 |
Earnings From Continuing Operations | 89.87 | 47.47 | -3.89 | -43.4 | -173.31 | -131.3 |
Minority Interest in Earnings | -6.1 | -0.18 | 5.39 | 3.77 | 10.93 | 0.53 |
Net Income | 83.77 | 47.29 | 1.5 | -39.63 | -162.38 | -130.77 |
Net Income to Common | 83.77 | 47.29 | 1.5 | -39.63 | -162.38 | -130.77 |
Net Income Growth | 607.00% | 3057.07% | - | - | - | - |
Shares Outstanding (Basic) | 409 | 430 | 374 | 396 | 406 | 409 |
Shares Outstanding (Diluted) | 409 | 430 | 374 | 396 | 406 | 409 |
Shares Change | -5.05% | 14.80% | -5.51% | -2.38% | -0.66% | -0.33% |
EPS (Basic) | 0.20 | 0.11 | 0.00 | -0.10 | -0.40 | -0.32 |
EPS (Diluted) | 0.20 | 0.11 | 0.00 | -0.10 | -0.40 | -0.32 |
EPS Growth | 644.59% | 2650.00% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 169.73 | 116.07 | 61.22 | -10.83 | -222.07 | -218.58 |
Free Cash Flow Per Share | 0.41 | 0.27 | 0.16 | -0.03 | -0.55 | -0.54 |
Gross Margin | 68.74% | 65.57% | 58.01% | 57.57% | 55.59% | 69.00% |
Operating Margin | 18.77% | 10.49% | -7.63% | -21.84% | -115.35% | -85.46% |
Profit Margin | 14.21% | 9.00% | 0.33% | -11.54% | -84.20% | -67.28% |
Free Cash Flow Margin | 28.79% | 22.09% | 13.35% | -3.16% | -115.15% | -112.46% |
EBITDA | 171.83 | 118.59 | 30.96 | -24.07 | -172.09 | -113.86 |
EBITDA Margin | 29.14% | 22.57% | 6.75% | -7.01% | -89.23% | -58.58% |
D&A For EBITDA | 61.17 | 63.45 | 65.94 | 50.92 | 50.36 | 52.24 |
EBIT | 110.65 | 55.13 | -34.98 | -74.99 | -222.45 | -166.1 |
EBIT Margin | 18.77% | 10.49% | -7.63% | -21.84% | -115.35% | -85.46% |
Effective Tax Rate | 20.18% | 30.65% | - | - | - | - |
Revenue as Reported | 525.41 | 525.41 | 458.74 | 343.26 | 192.85 | 194.36 |
Advertising Expenses | - | 0.68 | 1.7 | 1.13 | 2.45 | - |